Clinical trial NCT04087733: Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery
Official title: Effectiveness of Liposomial Ozonized-Oil on Ocular Microbial Flora Before Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ocular Infections
Lead sponsor: University of Molise
Sponsor class: OTHER
Collaborators: name: Azienda Policlinico Umberto I, Roma
name: Università degli Studi del Molise, Clinica Oculistica
name: Clinica Mediterranea, Napoli
name: Ospedale Santa Croce-Carle Cuneo
name: Centro Medico Oculistico ALSO, Saronno
name: Fondazione G.B. Bietti, IRCCS , Roma
name: Ospedale San Carlo di Nancy, Roma
name: Centro oftalmologico LASERVISTA, Caserta
name: Casa di cura GEPOS, Telese
name: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
name: Ospedale generale regionale F. Miulli, Acquaviva delle Fonti
name: Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
name: Ospedale Policlinico Casilino, Roma
name: Ospedale G. Panico, Tricase
name: Studio oculistico Laborante
name: Studio oculistico Franchini
name: U.C.O Ospedali Civico di Cristina Benfratelli
name: A.O.U. Città della Salute e della Scienza - Molinette Hospital
First posted: 2019-09-12
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: GROUP / TREATED EYE (OZODROP® ): OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.

GROUP / CONTROL EYE: saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery.
Primary purpose: OTHER

Brief summary: Evaluation of the antimicrobial efficacy of a liposomal ozone-based solution (OZODROP®) , vs placebo in 200 patients undergoing cataract surgery by phacoemulsification .

The clinical trial will last 3 days of treatment per patient. The conjunctival swab will be taken for each of the two eyes (in treatment and control) at T0 (before starting the treatment - 3 days before the cataract surgery) and at T3 (after 3 days of treatment - immediately before the cataract surgery). The last OZODROP instillation will take place 10 minutes before taking the sample.

Detailed description: The aim of the study is to assess the efficacy of a liposomal ozone-based solution (OZODROP®) in the preparation of the patient for cataract surgery, by evaluating the reduction of bacterial colonization of the conjunctiva.

The study will be carried out at 18 surgical centers located throughout the national territory and will be conducted in accordance with the recommendations of Italian ethics committees.

An informed consent will be provided to all study participants. 400 eyes of 200 patients undergoing cataract surgery by phacoemulsification will be included in the study. The clinical sample is divided into two groups, study group which will include treated and (GS) and control group (GC) eyes. The study group will be treated with OZODROP®, an isotonic ophthalmic solution composed of 0.5% ozonized oil in liposomes and hypromellose, while the GC will receive saline solution.

At the time of recruitment, all eyes will undergo a complete examination, as usual, and the patient enrolled in the study will be shown how to proceed.

The study includes 2 times, (T0) and (T3), equal for both groups in the study. 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the untreated contralateral eye will serve as a control.Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory. The reduction of conjunctival microbial flora, expressed as CFU, will be evaluated.

Through the analysis of the parameters in the study, a significant reduction in the microbial flora of the conjunctiva is expected in patients undergoing treatment with OZODROP®.

Eligibility criteria: Inclusion Criteria:

1. Age over 18 years
2. Patients eligible for cataract surgery
3. Willingness to participate in the study following the indications

Exclusion Criteria:

1. Use of topical and / or systemic antibiotics and other topical antiseptics during the study
2. Presence of topical ocular therapies that cannot be suspended for the entire duration of the study
3. Ongoing ocular or systemic inflammatory or infectious processes
4. Hypersensitivity to the constituents of the preparation in study

Primary outcomes:
measure: Reduction of conjunctival bacterial load assessed by CFU (Colony Forming Units) using Ozodrop in 200 patients before cataract surgery
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Campobasso
country: Italy
facility: University of Molise
Study officials:
affiliation: University of Molise
name: Ciro Costagliola
role: PRINCIPAL_INVESTIGATOR
References: